Department of Radiology, MC2026, 5841 S Maryland Avenue, University of Chicago, Chicago, IL 60637, USA.
Acad Radiol. 2011 Dec;18(12):1467-74. doi: 10.1016/j.acra.2011.07.017. Epub 2011 Oct 1.
The aims of this study were to evaluate high spectral and spatial resolution (HiSS) magnetic resonance imaging (MRI) for the diagnosis of breast cancer without the injection of contrast media by comparing the performance of precontrast HiSS images to that of conventional contrast-enhanced, fat-suppressed, T1-weighted images on the basis of image quality and in the task of classifying benign and malignant breast lesions.
Ten benign and 44 malignant lesions were imaged at 1.5 T with HiSS (precontrast administration) and conventional fat-suppressed imaging (3-10 minutes after contrast administration). This set of 108 images, after randomization, was evaluated by three experienced radiologists blinded to the imaging technique. Breast Imaging Reporting and Data System morphologic criteria (lesion shape, lesion margin, and internal signal intensity pattern) and final assessment were used to measure reader performance. Image quality was evaluated on the basis of boundary delineation and quality of fat suppression. An overall probability of malignancy was assigned to each lesion for HiSS and conventional images separately.
On boundary delineation and quality of fat suppression, precontrast HiSS scored similarly to conventional postcontrast MRI. On benign versus malignant lesion separation, there was no statistically significant difference in receiver-operating characteristic performance between HiSS and conventional MRI, and HiSS met a reasonable noninferiority condition.
Precontrast HiSS imaging is a promising approach for showing lesion morphology without blooming and other artifacts caused by contrast agents. HiSS images could be used to guide subsequent dynamic contrast-enhanced MRI scans to maximize spatial and temporal resolution in suspicious regions. HiSS MRI without contrast agent injection may be particularly important for patients at risk for contrast-induced nephrogenic systemic fibrosis or allergic reactions.
本研究旨在通过比较增强前高光谱和空间分辨率(HiSS)磁共振成像(MRI)与常规对比增强、脂肪抑制、T1 加权成像的图像质量和良恶性乳腺病变分类任务,评估其在不注射造影剂的情况下诊断乳腺癌的能力。
10 例良性和 44 例恶性病变在 1.5T 下进行 HiSS(增强前)和常规脂肪抑制成像(增强后 3-10 分钟)。将这 108 组图像随机分组,由 3 位有经验的放射科医生进行评估,他们对成像技术不知情。乳腺成像报告和数据系统形态学标准(病变形状、病变边缘和内部信号强度模式)和最终评估用于测量读者的表现。图像质量评估基于边界描绘和脂肪抑制质量。分别为 HiSS 和常规图像中的每个病变分配整体恶性概率。
在边界描绘和脂肪抑制质量方面,增强前 HiSS 与常规增强 MRI 评分相似。在良性与恶性病变分离方面,HiSS 和常规 MRI 的受试者工作特征性能无统计学差异,且 HiSS 符合合理的非劣效条件。
增强前 HiSS 成像技术是一种很有前途的方法,可以在不出现造影剂引起的blooming 等伪影的情况下显示病变形态。HiSS 图像可用于指导随后的动态对比增强 MRI 扫描,以最大化可疑区域的空间和时间分辨率。在造影剂诱导的肾源性系统性纤维化或过敏反应风险较高的患者中,不注射造影剂的 HiSS MRI 可能尤为重要。